Clonal chromosomal abnormalities in CD34
þ /CD38 À hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors Clonal chromosomal abnormalities in Philadelphia-negative cells (CCA/Ph-) have been identified in 3-15% of chronic myeloid leukemia (CML) patients with a partial or complete cytogenetic response (CCyR) to imatinib. 1 Trisomy 8 and deletions of chromosome 7 (either monosomy 7 or del 7(q)) account for the majority of cases, although a range of other karyotypic changes were seen at lower frequency. A recent study reported CCA/PhÀ in patients on dasatinib, indicating that the phenomenon is not limited to imatinib therapy. In some patients, CCA/PhÀ is associated with a myelodysplastic syndrome, and progression to acute myeloid leukemia has been reported. 1, 2 A single-center report suggested inferior survival in newly diagnosed patients who develop CCA/Ph-. 3 However, a larger study found that CCA/Ph-does not adversely affect the prognosis of patients with a major cytogenetic response to imatinib, indicating that this is a mostly benign condition. 4 The reported incidence of CCA/Ph-is based on metaphase karyotyping, which is limited by the small number of cells analyzed and by the fact that only cells are assayed that can be induced to divide within the culture period. We thus hypothesized that conventional karyotyoping may underestimate the incidence of CCA/Ph-and decided to screen CD34 þ /CD38 À cells from a cohort of CML patients with a CCyR to tyrosine kinase inhibitor (TKI) therapy for abnormalities of chromosomes 7 and 8. This primitive cell compartment is known to be enriched for hematopoietic progenitor and stem cells. 5 We find CCA/Ph-in CD34 þ /CD38 À cells from 4 of 19 patients, suggesting that CCA/Ph-is more common than previously appreciated.
Patients and methods

Patients
Samples were from consecutive CML patients on TKI therapy who were undergoing bone marrow aspirates at the Oregon Health & Science University as part of their clinical care. The only selection criterion was a normal karyotype on the previous biopsy. At the start of TKI therapy, one patient (number 14) was in the accelerated phase, whereas all others were in the chronic phase. All patients provided informed consent to an institutional review boardapproved protocol. Control samples (normal bone marrow mononuclear cells) were purchased from a commercial supplier.
Cell selection
Mononuclear cells were separated from bone marrow by density gradient centrifugation using Ficoll (Nycomed, Oslo, Norway) and depleted of lineage-positive cells using an antibody cocktail and magnetic beads (Stem Cell Technologies, Vancouver, British Columbia, Canada). CD34 þ /CD38 À (and in some experiments CD34 þ /CD38 þ ) cells were sorted on a BD FACSARIA after staining with fluorescein isothiocyanateconjugated anti-CD34 and phycoerythrin-conjugated anti-CD38 monoclonal antibodies (BD Biosciences, San José, CA, USA). Sorted cells were sedimented at 1000 g and resuspended in 1.2 ml 3:1 methanol: acetic acid. Cells were then dropped onto glass slides and allowed to dry one drop at a time.
FISH
Interphase fluorescence in situ hybridization (I-FISH) for BCR-ABL was performed on 200 unselected bone marrow cells as part of routine diagnostics, using the Vysis ABL (9q34, red), ASS Letters to the Editor (9q34, aqua) and BCR (22q11.2, green) probes (Vysis, Downer's Grove, IL, USA). Cells sorted using fluorescence-activated cell sorting and were subjected to I-FISH for chromosomes 7 and 8 abnormalities, using the Vysis D7S522 (7q31, red), CEP7 (green) and CEP8 (aqua) probes in a single co-hybridization assay (Figure 1a ). Samples were analyzed under a Nikon Eclipse E800 photoscope (Melville, NY, USA), and representative photographs were taken using CytoVision software from Applied Imaging (Santa Clara, CA, USA). We aimed to analyze 100 cells, the coordinates of which were recorded. In case of ambiguous results, additional 100 cells were analyzed if possible. To assess the BCR-ABL status of cells with chromosome 7/8 abnormalities, the slides were 'stripped' using 2 Â SSC/0.3% NP-40 and re-hybridized with the BCR-ABL probe. Individual cells were identified by their previously recorded coordinates and analyzed for colocalization of BCR and ABL signals. All samples were analyzed by two independent observers.
Statistical analysis
Categorical variables were analyzed by w 2 -test and noncategorical variables with the Mann-Whitney U-test.
Results and discussion
In the initial experiments, we analyzed CD34 þ /CD38 þ cells from two patients with known trisomy 8 in Ph-negative cells and one patient with a normal karyotype. In both trisomy 8 patients, metaphase karyotyping confirmed the previously detected abnormality in 9 of 20 cells (45%), and I-FISH on unselected marrow was positive in 29 and 15%, respectively. Of the CD34 þ /CD38 þ cells, 35 of 58 (60%) and 15 of 34 (44%) exhibited trisomy 8, suggesting a concordance between metaphase karyotyping and I-FISH of CD34 þ /CD38 þ cells. No abnormal interphases were seen in the normal control sample. To interrogate a more primitive cell compartment, we sorted CD34 þ /CD38 À cells from additional 19 patients and 4 normal controls using fluorescence-activated cell sorting (Table 1) . Analyzing 100 cells as planned succeeded in only 10 of 19 CML samples and on average, 66 ± 40 cells were available for scoring by I-FISH. Abnormal signal patterns were identified in 4 of 19 CML patients (21%) but in none of the normal controls (P ¼ 0.456). Abnormalities were trisomy 8, monosomy 7 and del(7q) (two patients). One additional patient (number 3) had trisomy 8 in 1 of 84 analyzable interphases; this is technically above the normal cutoff of 1%, but no additional cells were available for analysis to verify the finding. There was no significant difference between samples with and without abnormalities with respect to the number of cells available for analysis (49 ± 42 vs 81 ± 64, P ¼ 0.36). Re-hybridization of the same slides with a BCR-ABL probe did not detect BCR-ABL in any of the cells with abnormalities (Figure 1b) . None of the biopsies showed dysplasia; however, in patient 11, marrow infiltration with a low-grade B-cell lymphoma (positive for CD19, 20, 22, 45; negative for CD34) was found. Follow-up karyotyping was normal for patients 2 (26 months) and 5 (2, 5, 8, 20 months). Patient 15 showed 3 of 20, 4 of 20 and 4 of 20 metaphases lacking the Y chromosome at 6, 12 and 24 months, respectively. There were no dysplastic changes in any of these subsequent biopsies. No follow-up is available for patients 8 and 11. We analyzed potential correlations between abnormalities in BCR-ABL-negative CD34 þ /CD38 À cells and sex, age, disease duration and duration of TKI therapy. Patients with abnormalities were significantly older (median, 72 years; range, 64-80) than patients without abnormalities (median, 57 years; range 40-74; P ¼ 0.02), while no other significant differences were seen. 
Letters to the Editor
Our data show that clonal chromosomal abnormalities in Ph-negative primitive (CD34 þ /CD38 À ) cells from CML patients with a CCyR and a normal karyotype are fairly common. Given that we were limited by the number of analyzable interphases and that we restricted our analysis to screening for abnormalities of chromosomes 8 and 7, it is possible that the frequency is even higher than evident from our data. None of the patients with chromosome 7/8 abnormalities had dysplastic morphological features, which is consistent with the overall low incidence of myelodysplastic syndrome in CML patients with CCA/Ph-. 4 Interestingly, patient 11 was found to have a marrow infiltration with a low-grade B-cell lymphoma. Although the lymphoma cells did not express CD34, it is possible that the CD34 þ / CD38
À cells with trisomy 8 that were present in this patient are part of the NHL clone. Unfortunately, no follow-up material is available to test this. Patients with abnormalities were significantly older than patients without, suggesting that CCA/Phmay be acquired over a lifetime. Alternatively, the number of residual normal stem cells in older patients may be smaller, which could place these cells under enhanced pressure to reestablish nonleukemic hematopoiesis in the presence of a TKI, resulting in enhanced genetic instability. We did not detect chromosome 7/8 abnormalities in four normal controls. However, this number is too small for a reliable comparison and it is possible that abnormalities would be detected in a larger and age-matched control group.
The question whether the acquisition of Ph is preceded by an as-yet unidentified genetic event has attracted considerable attention ever since the first report of a bias of glucose-6-phosphate dehydrogenase isoenzyme expression in Ph-negative EBV-transformed B cell lines toward the phenotype of the Ph-positive CML cells. 6 CCA/Ph-, with rare exceptions, does not fit this model, given that the same specific cytogenetic abnormalities are not usually present in Ph-negative as well as in Ph-positive cells. At face value, the fact that Ph-negative hematopoiesis of patients with CCyR to interferon-a or imatinib is polyclonal 7, 8 argues against a Ph-negative pathological state. However, one must bear in mind that a hematopoietic stem cell could acquire a mutation that confers genetic instability, but not a competitive advantage over normal cells. This hypothetical parent cell could give rise to multiple related abnormal cell clones, one being the BCR-ABL-positive CML clone, and the others CCA/Ph-clones that become visible only on CCyR induction by TKIs. Alternatively, multiple unrelated abnormal clones could result from simultaneous or successive damage to multiple hematopoietic stem cells. In CML patients, this could occur during the re-establishment of Ph-negative hematopoiesis in the presence of TKIs, which may place considerable stress on a small pool of residual normal cells, perhaps enhanced by TKI inhibition of stem cell factor receptor or other critical pathways. To distinguish between the two fundamental possibilities, it will be necessary to establish the clonal relationship between the Phpositive and abnormal Ph-negative cell clones. Recent data from patients with Ph-negative myeloproliferative neoplasms suggest that both scenarios are possible. 9 Despite the fact that trisomy 8 and chromosome 7 deletions are associated with myelodysplastic syndrome and acute myeloid leukemia, most CML with CCA/Ph-have a favorable outcome, suggesting a requirement for cooperating mutations to produce these phenotypes. In CML patients on TKI therapy, the risk of such additional mutations must be small, and therefore their prognosis is usually favorable. Myelodysplastic syndromes (MDSs) are a heterogeneous group of malignancies characterized by dysplasia, cytopenia, ineffective hematopoiesis and by an increased risk of transformation to acute myeloid leukemia (AML). This risk is increased from refractory cytopenia with unilineage dysplasia, for example, refractory anemia (RA), with about 2% of cases progressing at 5 years to about 40% in cases with RA with excess blasts (RAEB-2). 1 Cytogenetic abnormalities have prognostic relevance and these have been incorporated into the IPSS score. 2 In contrast, only little is known about molecular aberrations in MDS, especially those associated with progression from MDS to AML. We speculated that in analogy to de novo AML, the etiology of MDS and of AML following MDS can also be viewed as a multistep process with the accumulation of activation mutations of tyrosine kinases (class I mutations) and loss-offunction mutations of hematopoietic transcription factors (class II mutations). 3 To support this hypothesis, we characterized our patient cohort (n ¼ 269) cytogenetically by means of chromosome banding analyses accompanied by fluorescence in situ hybridization, and on the molecular level by analyzing gene mutations frequently detected in MDS and/or AML, that is, mutations of RUNX1, FLT3, MLL, NRAS and NPM1. Fresh blood or bone marrows were obtained between August 2005 and October 2008 from a total of 269 unselected patients after informed written consent was obtained in accordance with the Declaration of Helsinki. The study was approved by the ethics committee of the Bayerische Landesärztekammer before its initiation. Twenty of these patients were analyzed at diagnosis of MDS and later at progression to s-AML following MDS (s-AML), whereas either the MDS sample or the s-AML was available in the residual 249 cases. In total, 188 MDS and 101 s-AML samples were analyzed. Diagnosis was according to standard World Health Organization (WHO) criteria. 4 MDS cases were analyzed at diagnosis except for the samples of 33 cases, which were not available at diagnosis but were analyzed during the course of their disease with a median time from diagnosis to analysis of 15.8 months. The composition of the MDS cohort is given in Table 1 . We included unclassified MDS cases (n ¼ 12) in our cohort only if additional cytogenetic or molecular aberrations could be identified confirming the presence of a neoplastic clone. Even though CMMLs are not classified as MDS according to the new WHO classification, we still included this entity because of the presence of myelodysplastic features, the published high transformation rate to AML (15-30% of cases) and the reported high incidence of RUNX1 mutations (RUNX1 þ ).
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